课题基金 / 基金详情

PEDIATRIC ONCOLOGY GROUP

PEDIATRIC ONCOLOGY GROUP
儿科肿瘤组
批准号:
6588181
负责人:
GREGORY H REAMAN
金额:
$858.74万
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-07-01 至 2003-02-28
关键词:
6 thiopurine Ewing's tumor Hodgkin's disease Wilms' tumor XomaZyme acivicin acute leukemia acute lymphocytic leukemia acute myelogenous leukemia adolescence (12-20) antineoplastics asparaginase astrocytoma biological response modifiers bone marrow transplantation brain neoplasms cancer registry /resource cancer risk central nervous system neoplasms child (0-11) chronic myelogenous leukemia cis platinum compound clinical research clinical trial phase I colony stimulating factor combination cancer therapy combination chemotherapy cooperative study cyclophosphamide cyclosporines cytosine arabinoside daunorubicin deferoxamine deoxycoformycin doxorubicin drug screening /evaluation enalapril ependymoma etoposide fazarabine fluorouracil germ cell neoplasms glioma hepatoblastoma hepatocellular carcinoma human genetic material tag human immunodeficiency virus 1 human subject human therapy evaluation human tissue ifosfamide interferons interleukin 2 medulloblastoma melphalan metastasis methotrexate mitoxantrone molecular oncology neoplasm /cancer chemotherapy neoplasm /cancer classification /staging neoplasm /cancer epidemiology neoplasm /cancer genetics neoplasm /cancer immunology neoplasm /cancer immunotherapy neoplasm /cancer pharmacology neoplasm /cancer radiation therapy neoplasm /cancer relapse /recurrence neoplasm /cancer surgery neuroblastoma nonHodgkin's lymphoma osteosarcoma paclitaxel pediatric neoplasm /cancer pediatric pharmacology podophyllin prednisone retinoate rhabdomyosarcoma tissue resource /registry topotecan trimetrexate vincristine

项目摘要

项目成果

GREGORY H REAMAN的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Pediatric Oncology Group (POG) is a multi-institutional, multidisciplinary cooperative Group whose goal is to control cancer among children and adolescents by therapeutic research aimed at improving the survival and quality of life. The 101 institutions and 1,906 individual members of POG pool their knowledge and resources to jointly develop and conduct a wide variety of large-scale clinical and laboratory studies. Member investigators include pediatric oncologists, pathologists, surgeons, radiation therapists, diagnostic radiologists, statisticians, clinical research assistants, oncology nurse specialists, and others who cooperate to improve the outcomes of treatment and better understand the biology of childhood cancer. Reference laboratories conduct an array of adjunct studies of biologic samples for genetic, molecular, and cellular characteristics with subsequent correlation of biologic features with patient characteristics and outcome, providing unique opportunities to address scientific questions relating to risk assessment, epidemiology, pathobiology and other cancer-related topics. The overall aims of this five-year renewal application are to increase cure rates of all forms of childhood cancer while simultaneously reducing the acute and late consequences of treatment by design of risk-based therapies. We also aim to increase accruals, reduce barriers to enrollment, improve long-term follow-up, and extend the benefits of clinical trials participation. Traditional outcome analyses and translational research will be supplemented by innovative studies of alternative endpoints, including costs and quality of life. The Operations Office is the central Group headquarters and provides the staff and support for the overall scientific, administrative, and fiscal management of the Group. The Operations Office functions include responsibilities for all interactions with NCI, review of individual and institutional membership status and performance, maintenance of the Group bibliography, responsibility for convening and conducting semiannual meetings, distribution of monthly mailings and minutes, oversight of quality control and institutional audits, responsibility for preparation and coordination of all protocols from concept/LOI through activation and revisions and amendments as necessary, and provision of logistical and financial support to scientific committees, and disbursement of third party payments where relevant for participants without cooperative agreements from NCI. In all aspects of general scientific oversight and development of research plans and analyses for each disease studied, the Operations Office works closely with the Statistical Office in a seamless coordination of effort. This application requests renewed and continued ending for the Operations Office and for the scientific committees, reference laboratories and key personnel of the Group.
期刊论文(170)
专著(0)
科研奖励(0)
会议论文
Rhabdomyosarcoma in children and adolescents. A review.
儿童和青少年的横纹肌肉瘤。
DOI: --
发表时间: 1987
期刊: Hematology/oncology clinics of North America
影响因子: --
作者: [Ruymann,FB]
通讯作者: Ruymann,FB
DOI: 10.1001/archotol.1987.01860110091014
发表时间: 1987
期刊: Archives of otolaryngology--head & neck surgery
影响因子: --
作者: [Wharam,MD, Beltangady,MS, Heyn,RM, Lawrence,W, RaneyJr,RB, Ruymann,FB, Soule,EH, Tefft,M, Maurer,HM]
通讯作者: Maurer,HM
Effectiveness of paclitaxel in treating papillary serous carcinoma of the peritoneum in an adolescent.
紫杉醇治疗青少年腹膜乳头状浆液性癌的有效性。
DOI: 10.1016/0002-9378(95)90046-2
发表时间: 1995
期刊: American journal of obstetrics and gynecology
影响因子: 9.8
作者: [Wall,JE, Mandrell,BN, Jenkins3rd,JJ, Smiley,LM, Pratt,CB]
通讯作者: Pratt,CB
DOI: 10.3171/jns.1991.74.6.0905
发表时间: 1991
期刊: Journal of neurosurgery
影响因子: 4.1
作者: [Krischer,JP, Ragab,AH, Kun,L, Kim,TH, Laurent,JP, Boyett,JM, Cornell,CJ, Link,M, Luthy,AR, Camitta,B]
通讯作者: Camitta,B
73
    Human Specimen Banking in NCI-Supported Cancer Clinical
    Support for Human Specimen Banking in NCI-Supported Cancer Clinical Trials
    Human Specimen Banking in NCI-Supported Cancer Clinical
    Support for Human Specimen Banking in NCI-Supported Cancer Clinical Trials